Contrast Agents/Media Global Market – Forecast To 2025

Publishing Date : October, 2018
Report Code : HCPH0109
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Chemical substances that improve the visibility of specific organs, tissues or blood vessel during a diagnostic imaging investigation are known as contrast agents. These substances are administered directly through veins, arteries, and joints or consumed orally. X-ray and computed tomography (CT) imaging exams makes use of iodinated and barium based contrast agents, whereas, Gadolinium-based contrast agents are preferred in MRI (Magnetic Resonance Imaging). These substances improve the reporting or accuracy of how internal structures of body are working and any associated abnormalities.  Ultrasound scans makes use of special contrast agents called microbubbles which strongly interact with the ultrasound beam and enhances the details of heart, liver and kidney.

As estimated by IQ4I Research, the contrast Agents global market is estimated to reach $6,879.0 million by 2025. The contrast agent global market by molecule is segmented into Iodine based [Ionic (Monomeric and Dimeric), Non-Ionic (Monomeric and Dimeric)], Gadolinium-based contrast agents [Macrocyclic (Ionic and Non-Ionic), Linear (Ionic and Non-Ionic)], microbubble based contrast agent and others which include Barium, iron and dyes. Iodine-based contrast agent market held the largest market revenue in 2018 and microbubble segment is growing rapidly at double digit CAGR from 2018 to 2025 due to expansion in disease indications. Based on ionicity, the Iodine-based contrast agent is segmented into ionic and non-ionic. Non-Ionic Iodine-based contrast agent market accounted the largest share. Non-ionic iodine contrast agents are used more because of lower osmolality, they are better tolerated and another advantage is that, they appear to have less toxicity. Ionic Iodine based contrasts are further segmented by its chemical structure into monomers and dimers. Monomers market accounted for the largest share. Non-Ionic Iodine based contrasts are further segmented by its chemical structure into monomeric and dimeric. Monomerics market accounted the largest share as they are safer and tolerable when compared to ionic contrast agent and low osmolar agents do not dissociate into a particle in solution and helps in reducing the neurotoxicity.

The contrast agents market by modality is segmented into X-Ray/CT, MRI and Ultrasound. X-Ray/CT market held the largest market revenue in 2018 and ultrasound segment is growing rapidly at double digit CAGR from 2018 to 2025 due to increased use in diagnostic procedures especially echocardiography, focal liver lesions and ultrasonography of urinary tract.

The contrast agents market by applications is segmented into cardiovascular, cancer, gastrointestinal, musculoskeletal, neurology, nephrology, obstetrics & gynecology, urology and others which include neck, liver and salivary gland imaging. Cardiovascular market accounted for the largest share and is the fastest growing market from 2018 to 2025 due to increase in a number of cardiac imaging procedures using Iodine, Gadolinium and microbubble contrast agents. Contrast agents market by route of administration is segmented into intravascular, oral, rectal and others which include intraosseous, intrathecal and intravesicle. Intravascular route of administration accounted for largest share and is the fastest growing market due to increase in incidence and prevalence of cardiovascular, cancer, neurology, nephrology related conditions which require Iodine, Gadolinium and microbubble contrast agent to be administered intravascular.

Contrast agents market by imaging is segmented into diagnostic and interventional imaging. Diagnostic imaging market held the largest market revenue and interventional imaging segment is growing at fast/rapidly at double digit CAGR from 2018 to 2025 due to increase in image guide procedures and increase in aging population who usually opt minimally invasive procedures.

Contrast agents market based on the end-user market is segmented into hospitals, diagnostic & ambulatory surgical centers and other which include academic and research institutes. Hospitals market accounted largest share in 2018 as there is a rise in demand for the diagnosis and interventional treatment of diseases using CT or X-Ray, MRI and ultrasound imaging procedures. Diagnostic & Ambulatory surgical centers is the fastest growing segment with mid single digit CAGR from 2018 to 2025 due to increase in number of diagnostic procedures related to musculoskeletal (arthroscopy, imaging of spine), gastrointestinal (imaging of abdomen, GI tract) and obstetrics & gynecology (hysterosalpingography).

Geographical wise, North America region commanded the largest revenue in 2018. Favorable reimbursement coverage and increase in incidence and prevalence of diseases conditions due to change in lifestyle, obesity has led the market growth in this region. However, Asia-Pacific region is the second leading market for contrast agents and is expected to grow at mid single CAGR from 2018 to 2025 due to increased healthcare awareness, economic growth, large patient pool and rising aged population.

The contrast agent global market is a competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares and also acquiring companies for product expansion. Some of the key players of the contrast agent market are GE Company (GE Healthcare) (U.S.), Bayer Group (Germany), Guerbet (France), Taejoon Pharm Co. Ltd., (South Korea), Beijing Beilu Pharmaceuticals Company Limited (China), Bracco Group (Italy), Fujifilm Holding Corporation (Japan), Sanochemia Pharmazeutika AG (Austria), Dongkook Lifescience (Korea), Lantheus medical imaging (U.S.) and Fujipharma Co. Ltd (Japan).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific 
  • Rest of the World (RoW)
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     REPORT SCOPE
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET CRACKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING DEMAND FOR DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY PROCEDURES
        • 3.3.1.2     INCREASE IN INCIDENCE AND PREVALENCE OF DISEASE CONDITIONS
        • 3.3.1.3     INCREASE IN AGING POPULATION
        • 3.3.1.4     EXPANSION IN INDICATIONS OF CONTRAST MEDIA MARKET
        • 3.3.1.5     THE GROWTH OF MEDICAL IMAGING TECHNOLOGIES IN EMERGING MARKETS
        • 3.3.1.6     INCREASING RESEARCH ACTIVITIES FOR CONTRAST AGENTS
        • 3.3.1.7     FAVORABLE REIMBURSEMENT
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     SIDE EFFECT ASSOCIATED WITH CONTRAST AGENTS.
        • 3.3.2.2     SHORTAGE OF RADIOLOGIST.
        • 3.3.2.3     AVAILABILITY OF ALTERNATIVE PRODUCTS
        • 3.3.2.4     STRINGENT REGULATIONS FOR CONTRAST AGENTS.
    • 3.4     REGULATORY GUIDELINES
      • 3.4.1     UNITED STATES
      • 3.4.2     EUROPE
      • 3.4.3     CHINA
      • 3.4.4     JAPAN
      • 3.4.5     INDIA
    • 3.5     REIMBURSEMENT SCENARIO
      • 3.5.1     REIMBURSEMENT TABLE
    • 3.6     UPCOMING TECHNOLOGY
    • 3.7     CLINICAL TRIALS
    • 3.8     PATENT TRENDS
    • 3.9     SUPPLY CHAIN ANALYSIS
    • 3.10     PORTER’S FIVE FORCE ANALYSIS
      • 3.10.1     THREAT OF NEW ENTRANTS
      • 3.10.2     THREAT OF SUBSTITUTES
      • 3.10.3     BARGAINING POWER OF SUPPLIERS
      • 3.10.4     BARGAINING POWER OF BUYERS
      • 3.10.5     RIVALRY AMONG EXISTING COMPETITORS
    • 3.11     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.11.1     CONTRAST AGENTS GLOBAL MARKET
      • 3.11.2     X-RAY/CT CONTRAST AGENTS MARKET
      • 3.11.3     MRI CONTRAST AGENTS MARKET
      • 3.11.4     ULTRASOUND BASED CONTRAST AGENTS MARKET
    • 3.12     CONTRAST AGENTS GLOBAL CONSUMPTION
  • 4     CONTRAST AGENTS GLOBAL MARKET, BY MOLECULE
    • 4.1     INTRODUCTION
    • 4.2     IODINE BASED CONTRAST MEDIA
      • 4.2.1     IODINE BASED IONIC CONTRAST MEDIA
        • 4.2.1.1     MONOMERS
        • 4.2.1.2     DIMER
      • 4.2.2     IODINE BASED NON-IONIC CONTRAST MEDIA
        • 4.2.2.1     MONOMER
        • 4.2.2.2     DIMER
    • 4.3     GADOLINIUM-BASED CONTRAST MEDIA
      • 4.3.1     MACROCYCLIC
        • 4.3.1.1     IONIC
        • 4.3.1.2     NON-IONIC
      • 4.3.2     LINEAR
        • 4.3.2.1     IONIC
        • 4.3.2.2     NON-IONIC
    • 4.4     MICROBUBBLE BASED CONTRAST MEDIA
    • 4.5     OTHER CONTRAST MEDIA
  • 5     CONTRAST AGENTS GLOBAL MARKET, BY MODALITY
    • 5.1     INTRODUCTION
    • 5.2     X-RAY/COMPUTED TOMOGRAPHY (CT)
    • 5.3     MAGNETIC RESONANCE IMAGING (MRI)
    • 5.4     ULTRASOUND
  • 6     CONTRAST AGENTS GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     CARDIOVASCULAR
    • 6.3     CANCER
    • 6.4     GASTROINTESTINAL
    • 6.5     MUSCULOSKELETAL
    • 6.6     NEUROLOGY
    • 6.7     NEPHROLOGY
    • 6.8     OBSTETRICS AND GYNECOLOGY
    • 6.9     UROLOGY
    • 6.10     OTHERS
  • 7     CONTRAST AGENTS GLOBAL MARKET, BY ROUTE OF ADMINISTRATION
    • 7.1     INTRODUCTION
    • 7.2     INTRAVASCULAR
    • 7.3     ORAL
    • 7.4     RECTAL
    • 7.5     OTHERS
  • 8     CONTRAST AGENTS GLOBAL MARKET, BY IMAGING
    • 8.1     INTRODUCTION
    • 8.2     DIAGNOSTIC IMAGING
    • 8.3     INTERVENTIONAL IMAGING
  • 9     CONTRAST AGENTS GLOBAL MARKET, BY END-USERS
    • 9.1     INTRODUCTION
    • 9.2     HOSPITAL
    • 9.3     DIAGNOSTIC & AMBULATORY SURGICAL CENTERS
    • 9.4     OTHER END-USER
  • 10     REGIONAL ANALYSIS
    • 10.1     INTRODUCTION
    • 10.2     NORTH AMERICA
      • 10.2.1     THE U.S.
      • 10.2.2     OTHERS
    • 10.3     EUROPE
      • 10.3.1     GERMANY
      • 10.3.2     U.K.
      • 10.3.3     FRANCE
      • 10.3.4     OTHERS
    • 10.4     ASIA-PACIFIC
      • 10.4.1     JAPAN
      • 10.4.2     CHINA
      • 10.4.3     KOREA
      • 10.4.4     OTHERS
    • 10.5     REST OF THE WORLD
      • 10.5.1     BRAZIL
      • 10.5.2     REST OF LATIN AMERICA
      • 10.5.3     MIDDLE EAST AND OTHERS
  • 11     COMPETITIVE LANDSCAPE
    • 11.1     INTRODUCTION
    • 11.2     APPROVALS
    • 11.3     OTHER KEY DEVELOPMENT
    • 11.4     COLLABORATION
    • 11.5     PARTNERSHIP
    • 11.6     AGREEMENT
    • 11.7     NEW PRODUCT LAUNCH
  • 12     MAJOR PLAYER PROFILES
    • 12.1     BAYER GROUP
      • 12.1.1     OVERVIEW
      • 12.1.2     FINANCIALS
      • 12.1.3     PRODUCT PORTFOLIO
      • 12.1.4     KEY DEVELOPMENTS
      • 12.1.5     BUSINESS STRATEGY
      • 12.1.6     SWOT ANALYSIS
    • 12.2     BEIJING BEILU PHARMACEUTICAL CO., LTD
      • 12.2.1     OVERVIEW
      • 12.2.2     FINANCIALS
      • 12.2.3     PRODUCT PORTFOLIO
      • 12.2.4     KEY DEVELOPMENTS
      • 12.2.5     BUSINESS STRATEGY
      • 12.2.6     SWOT ANALYSIS
    • 12.3     BRACCO GROUP
      • 12.3.1     OVERVIEW
      • 12.3.2     FINANCIALS
      • 12.3.3     PRODUCT PORTFOLIO
      • 12.3.4     KEY DEVELOPMENTS
      • 12.3.5     BUSINESS STRATEGY
      • 12.3.6     SWOT ANALYSIS
    • 12.4     DONGKOOK LIFE SCIENCE
      • 12.4.1     OVERVIEW
      • 12.4.2     FINANCIALS
      • 12.4.3     PRODUCT PORTFOLIO
      • 12.4.4     KEY DEVELOPMENTS
      • 12.4.5     BUSINESS STRATEGY
      • 12.4.6     SWOT ANALYSIS
    • 12.5     FUJIFILM HOLDINGS CORPORATION
      • 12.5.1     OVERVIEW
      • 12.5.2     FINANCIALS
      • 12.5.3     PRODUCT PORTFOLIO
      • 12.5.4     KEY DEVELOPMENTS
      • 12.5.5     BUSINESS STRATEGY
      • 12.5.6     SWOT ANALYSIS
    • 12.6     FUJIPHARMA CO LTD
      • 12.6.1     OVERVIEW
      • 12.6.2     FINANCIALS
      • 12.6.3     PRODUCT PORTFOLIO
      • 12.6.4     KEY DEVELOPMENTS
      • 12.6.5     BUSINESS STRATEGY
      • 12.6.6     SWOT ANALYSIS
    • 12.7     GE COMPANY (GE HEALTHCARE)
      • 12.7.1     OVERVIEW
      • 12.7.2     FINANCIALS
      • 12.7.3     PRODUCT PORTFOLIO
      • 12.7.4     KEY DEVELOPMENTS
      • 12.7.5     BUSINESS STRATEGY
      • 12.7.6     SWOT ANALYSIS
    • 12.8     GUERBET
      • 12.8.1     OVERVIEW
      • 12.8.2     FINANCIALS
      • 12.8.3     PRODUCT PORTFOLIO
      • 12.8.4     KEY DEVELOPMENTS
      • 12.8.5     BUSINESS STRATEGY
      • 12.8.6     SWOT ANALYSIS
    • 12.9     LANTHEUS MEDICAL IMAGING INC.
      • 12.9.1     OVERVIEW
      • 12.9.2     FINANCIALS
      • 12.9.3     PRODUCT PORTFOLIO
      • 12.9.4     KEY DEVELOPMENTS
      • 12.9.5     BUSINESS STRATEGY
      • 12.9.6     SWOT ANALYSIS
    • 12.10     SANOCHEMIA PHARMACEUTICAL AG
      • 12.10.1     OVERVIEW
      • 12.10.2     FINANCIALS
      • 12.10.3     PRODUCT PORTFOLIO
      • 12.10.4     KEY DEVELOPMENTS
      • 12.10.5     BUSINESS STRATEGY
      • 12.10.6     SWOT ANALYSIS
    • 12.11     TAEJOON PHARM CO., LTD
      • 12.11.1     OVERVIEW
      • 12.11.2     FINANCIALS
      • 12.11.3     PRODUCT PORTFOLIO
      • 12.11.4     KEY DEVELOPMENTS
      • 12.11.5     BUSINESS STRATEGY
      • 12.11.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 2     MRI CONTRAST AGENT GLOBAL CONSUMPTION, (2017-2025) (L)
      • TABLE 3     X-RAY/CT CONTRAST AGENTS GLOBAL CONSUMPTION, (2017-2025) (L)
      • TABLE 4     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY MOLECULE, (2017-2025) ($MN)
      • TABLE 5     IODINE BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 6     IODINE BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 7     IODINE BASED IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 8     IODINE BASED IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 9     IODINE BASED IONIC MONOMER CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 10     IODINE BASED IONIC DIMER CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 11     IODINE BASED NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 12     IODINE BASED NON-IONIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 13     IODINE BASED NON-IONIC MONOMER CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 14     IODINE BASED NON-IONIC DIMER CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 15     GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 16     GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 17     MACROCYCLIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 18     MACROCYCLIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 19     MACROCYCLIC IONIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 20     MACROCYCLIC NON-IONIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 21     LINEAR GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 22     LINEAR GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 23     LINEAR IONIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 24     LINEAR NON-IONIC GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 25     MICROBUBBLE BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 26     OTHER CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 27     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY MODALITY, (2017-2025) ($MN)
      • TABLE 28     X-RAY/CT GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 29     MAGNETIC RESONANCE IMAGING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 30     ULTRASOUND GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 31     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 32     CARDIOVASCULAR GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 33     CANCER GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 34     GASTROINTESTINAL GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 35     MUSCULOSKELETAL GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 36     NEUROLOGY GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 37     NEPHROLOGY GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 38     OBSTETRICS AND GYNECOLOGY GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 39     UROLOGY GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 40     OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 41     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2017-2025) ($MN)
      • TABLE 42     INTRAVASCULAR GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 43     ORAL GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 44     RECTAL GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 45     OTHER GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 46     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY IMAGING, (2017-2025) ($MN)
      • TABLE 47     DIAGNOSTIC IMAGING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 48     INTERVENTIONAL IMAGING GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 49     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY END-USERS, (2017-2025) ($MN)
      • TABLE 50     CONTRAST AGENTS HOSPITAL GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 51     CONTRAST AGENTS DIAGNOSTIC & AMBULATORY SURGICAL CENTER GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 52     OTHER END-USERS CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 53     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 54     NORTH AMERICA CONTRAST AGENTS MARKET REVENUE, BY MOLECULE, (2017-2025) ($MN)
      • TABLE 55     NORTH AMERICA IODINE BASED CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 56     NORTH AMERICA IODINE BASED IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 57     NORTH AMERICA IODINE BASED NON-IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 58     NORTH AMERICA GADOLINIUM-BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 59     NORTH AMERICA MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 60     NORTH AMERICA LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 61     NORTH AMERICA CONTRAST AGENTS MARKET REVENUE, BY MODALITY, (2017-2025) ($MN)
      • TABLE 62     NORTH AMERICA CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 63     NORTH AMERICA CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2017-2025) ($MN)
      • TABLE 64     NORTH AMERICA CONTRAST AGENTS MARKET REVENUE, BY IMAGING, (2017-2025) ($MN)
      • TABLE 65     NORTH AMERICA CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2017-2025) ($MN)
      • TABLE 66     NORTH AMERICA CONTRAST AGENTS GLOBAL MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
      • TABLE 67     EUROPE CONTRAST AGENTS MARKET REVENUE, BY MOLECULE, (2017-2025) ($MN)
      • TABLE 68     EUROPE IODINE BASED CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 69     EUROPE IODINE BASED IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 70     EUROPE IODINE BASED NON-IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 71     EUROPE GADOLINIUM-BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 72     EUROPE MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 73     EUROPE LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 74     EUROPE CONTRAST AGENTS MARKET REVENUE, BY MODALITY, (2017-2025) ($MN)
      • TABLE 75     EUROPE CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 76     EUROPE CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2017-2025) ($MN)
      • TABLE 77     EUROPE CONTRAST AGENTS MARKET REVENUE, BY IMAGING, (2017-2025) ($MN)
      • TABLE 78     EUROPE CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2017-2025) ($MN)
      • TABLE 79     EUROPE CONTRAST AGENTS GLOBAL MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
      • TABLE 80     ASIA-PACIFIC CONTRAST AGENTS MARKET REVENUE, BY MOLECULE, (2017-2025) ($MN)
      • TABLE 81     ASIA-PACIFIC IODINE BASED CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 82     ASIA-PACIFIC IODINE BASED IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 83     ASIA-PACIFIC IODINE BASED NON-IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 84     ASIA-PACIFIC GADOLINIUM-BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 85     ASIA-PACIFIC MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 86     ASIA-PACIFIC LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 87     ASIA-PACIFIC CONTRAST AGENTS MARKET REVENUE, BY MODALITY, (2017-2025) ($MN)
      • TABLE 88     ASIA-PACIFIC CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 89     ASIA-PACIFIC CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2017-2025) ($MN)
      • TABLE 90     ASIA-PACIFIC CONTRAST AGENTS MARKET REVENUE, BY IMAGING, (2017-2025) ($MN)
      • TABLE 91     ASIA-PACIFIC CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2017-2025) ($MN)
      • TABLE 92     ASIA-PACIFIC CONTRAST AGENTS GLOBAL MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
      • TABLE 93     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY MOLECULE, (2017-2025) ($MN)
      • TABLE 94     REST OF THE WORLD IODINE BASED CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 95     REST OF THE WORLD IODINE BASED IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 96     REST OF THE WORLD IODINE BASED NON-IONIC CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 97     REST OF THE WORLD GADOLINIUM-BASED CONTRAST AGENTS MARKET REVENUE, BY CHEMICAL STRUCTURE, (2017-2025) ($MN)
      • TABLE 98     REST OF THE WORLD MACROCYCLIC CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 99     REST OF THE WORLD LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2017-2025) ($MN)
      • TABLE 100     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY MODALITY, (2017-2025) ($MN)
      • TABLE 101     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 102     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION, (2017-2025) ($MN)
      • TABLE 103     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY IMAGING, (2017-2025) ($MN)
      • TABLE 104     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2017-2025) ($MN)
      • TABLE 105     REST OF THE WORLD CONTRAST AGENTS GLOBAL MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
      • TABLE 106     APPROVALS (2016-2018)
      • TABLE 107     OTHER KEY DEVELOPMENT, (2016-2018)
      • TABLE 108     COLLABORATION, (2016-2018)
      • TABLE 109     PARTNERSHIP, (2016-2018)
      • TABLE 110     AGREEMENT, (2016-2018)
      • TABLE 111     NEW PRODUCT LAUNCH, (2016-2018)
      • TABLE 112     BAYER GROUP: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 113     BAYER GROUP: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
      • TABLE 114     BAYER GROUP: TOTAL REVENUE, BY GEOGRAPHY (2016-2018) ($MN)
      • TABLE 115     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2016 – 2018) ($MN)
      • TABLE 116     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
      • TABLE 117     FUJIFILM HOLDING CORPORATION: TOTAL REVENUE, BY GEOGRAPHY (2016 – 2018) ($MN)
      • TABLE 118     FUJIPHARMA CO LTD: TOTAL REVENUE AND R&D EXPENSES, (2016–2018) ($MN)
      • TABLE 119     FUJIPHARMA CO LTD: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
      • TABLE 120     GE COMPANY: TOTAL REVENUE AND R&D EXPENSES (2016 – 2018) ($MN)
      • TABLE 121     GE COMPANY: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
      • TABLE 122     GE COMPANY: TOTAL REVENUE, BY GEOGRAPHY (2016 –2018) ($MN)
      • TABLE 123     GUERBET: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 124     GUERBET: SEGMENTAL REVENUE (2015-2017) ($MN)
      • TABLE 125     GUERBET: GEOGRAPHIC REVENUE (2015-2017) ($MN)
      • TABLE 126     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 127     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY PRODUCTS (2016-2018) ($MN)
      • TABLE 128     LANTHEUS MEDICAL IMAGING INC.: TOTAL REVENUE, BY GEOGRAPHY (2016-2018) ($MN)
      • TABLE 129     SANOCHEMIA PHARMACEUTICAL AG: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 130     SANOCHEMIA PHARMACEUTICAL AG: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)

      LIST OF FIGURES

      • FIGURE 1     CONTRAST AGENTS GLOBAL MARKET SHARE AND REVENUE, BY REGION, (2017-2025) ($MN), 2018 (%)
      • FIGURE 2     RESEARCH METHODOLOGY: CONTRAST AGENTS GLOBAL MARKET
      • FIGURE 3     CONTRAST AGENTS GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     CONTRAST AGENTS GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     CONTRAST AGENTS GLOBAL MARKET: MARKET CRACKDOWN AND DATA TRIANGULATION
      • FIGURE 6     CONTRAST AGENTS GLOBAL MARKET: MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     CONTRAST AGENTS GLOBAL MARKET: PATENT FILING BY MAJOR PLAYERS (2013–2018)
      • FIGURE 9     CONTRAST AGENTS GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 10     CONTRAST AGENTS MARKET: PORTER’S ANALYSIS
      • FIGURE 11     CONTRAST AGENTS GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2018 (%)
      • FIGURE 12     X-RAY/CT CONTRAST AGENTS MARKET: MAJOR PLAYER ANALYSIS (2018) (%)
      • FIGURE 13     MRI CONTRAST AGENTS MARKET: MAJOR PLAYER ANALYSIS (2018) (%)
      • FIGURE 14     ULTRASOUND BASED CONTRAST AGENTS: MAJOR PLAYER ANALYSIS (2018) (%)
      • FIGURE 15     REGIONAL AND COUNTRYWISE CONSUMPTION OF MRI CONTRAST AGENTS IN SHARE AND LITERS: (2018)(%)(L)
      • FIGURE 16     REGIONAL AND COUNTRYWISE CONSUMPTION OF X-RAY/CT CONTRAST AGENTS IN SHARE AND LITERS: (2018) (%) (L)
      • FIGURE 17     CONTRAST AGENTS GLOBAL MARKET SHARE, BY MOLECULE (2018 V/S 2025) (%)
      • FIGURE 18     IODINE BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY IONICITY (2018 V/S 2025) (%)
      • FIGURE 19     IODINE BASED IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 20     IODINE BASED IONIC MONOMER CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 21     IODINE BASED NON-IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BY CHEMICAL STRUCTURE (2018 V/S 2025) (%)
      • FIGURE 22     IODINE BASED NON-IONIC CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 23     IODINE BASED NON-IONIC MONOMER CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 24     GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET REVENUE, BY CHEMICAL STRUCTURE (2017-2025) ($MN)
      • FIGURE 25     GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 26     LINEAR GADOLINIUM-BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 27     MICROBUBBLE BASED CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 28     OTHER CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 29     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY MODALITY (2017-2025) ($MN)
      • FIGURE 30     CONTRAST AGENTS GLOBAL MARKET SHARE, BY APPLICATION (2018) (%)
      • FIGURE 31     CARDIOVASCULAR GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 32     GASTROINTESTINAL GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 33     MUSCULOSKELETAL GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 34     NEPHROLOGY GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 35     OBSTETRICS AND GYNECOLOGY GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 36     UROLOGY GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 37     OTHER APPLICATIONS GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 38     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY ROUTE OF ADMINISTRATION (2018) ($MN)
      • FIGURE 39     INTRAVASCULAR GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 40     ORAL GLOBAL MARKET REVENUE, BY REGION (2018-2025) ($MN)
      • FIGURE 41     RECTAL GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN)
      • FIGURE 42     OTHER GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN)
      • FIGURE 43     CONTRAST AGENTS GLOBAL MARKET SHARE, BY IMAGING (2018 V/S 2025) (%)
      • FIGURE 44     DIAGNOSTIC IMAGING GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 45     INTERVENTIONAL IMAGING PROCEDURAL SHARE (%)
      • FIGURE 46     CONTRAST AGENTS GLOBAL MARKET SHARE, BY END-USERS, (2018 V/S 2025) (%)
      • FIGURE 47     HOSPITAL GLOBAL MARKET SHARE, BY END-USERS, (2018 V/S 2025) (%)
      • FIGURE 48     DIAGNOSTIC & AMBULATORY SURGICAL CENTER GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 49     OTHER END-USER GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 50     CONTRAST AGENTS GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN), CAGR (%)
      • FIGURE 51     CONTRAST AGENTS GLOBAL MARKET SHARE, BY REGION AND COUNTRY (2018) (%)
      • FIGURE 52     NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY MOLECULE AND IODINE BASED CONTRAST AGENTS MARKET SHARE BY IONICITY, (2018 V/S 2025) (%)
      • FIGURE 53     NORTH AMERICA IODINE BASED IONIC AND NON-IONIC CONTRAST AGENTS MARKET SHARE BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%)
      • FIGURE 54     NORTH AMERICA GADOLINIUM-BASED CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%) AND MACROCYCLIC, LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018 V/S 2025) ($MN)
      • FIGURE 55     NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY MODALITY, AND CONTRAST AGENTS MARKET SHARE, BY IMAGING, (2018 V/S 2025) (%)
      • FIGURE 56     NORTH AMERICA CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 57     NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION AND END-USER, (2018 V/S 2025) (%)
      • FIGURE 58     NORTH AMERICA CONTRAST AGENTS MARKET SHARE, BY COUNTRY, (2018 V/S 2025) (%)
      • FIGURE 59     U.S. CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
      • FIGURE 60     U.S. CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 61     U.S. CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
      • FIGURE 62     U.S. CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
      • FIGURE 63     OTHER NORTH AMERICAN COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
      • FIGURE 64     OTHER NORTH AMERICAN COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 65     OTHER NORTH AMERICAN COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
      • FIGURE 66     OTHER NORTH AMERICAN COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
      • FIGURE 67     EUROPE CONTRAST AGENTS MARKET SHARE, BY MOLECULE AND IODINE BASED CONTRAST AGENTS MARKET SHARE BY IONICITY, (2018 V/S 2025) (%)
      • FIGURE 68     EUROPE IODINE BASED IONIC AND NON-IONIC CONTRAST AGENTS MARKET SHARE BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%)
      • FIGURE 69     EUROPE GADOLINIUM-BASED CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%) AND MACROCYCLIC, LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018 V/S 2025) ($MN)
      • FIGURE 70     EUROPE CONTRAST AGENTS MARKET SHARE, BY MODALITY, AND CONTRAST AGENTS MARKET SHARE, BY IMAGING, (2018 V/S 2025) (%)
      • FIGURE 71     EUROPE CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 72     EUROPE CONTRAST AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION AND END-USER, (2018 V/S 2025) (%)
      • FIGURE 73     EUROPE CONTRAST AGENTS MARKET SHARE, BY COUNTRY, (2018 V/S 2025) (%)
      • FIGURE 74     GERMANY CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
      • FIGURE 75     GERMANY CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 76     GERMANY CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
      • FIGURE 77     GERMANY CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
      • FIGURE 78     U.K. CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
      • FIGURE 79     U.K. CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 80     U.K. CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
      • FIGURE 81     U.K. CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
      • FIGURE 82     FRANCE CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
      • FIGURE 83     FRANCE CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 84     FRANCE CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
      • FIGURE 85     FRANCE CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
      • FIGURE 86     OTHER EUROPEAN COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
      • FIGURE 87     OTHER EUROPEAN COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 88     OTHER EUROPEAN COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
      • FIGURE 89     OTHER EUROPEAN COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
      • FIGURE 90     ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY MOLECULE AND IODINE BASED CONTRAST AGENTS MARKET SHARE BY IONICITY, (2018 V/S 2025) (%)
      • FIGURE 91     ASIA-PACIFIC IODINE BASED IONIC AND NON-IONIC CONTRAST AGENTS MARKET SHARE BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%)
      • FIGURE 92     ASIA-PACIFIC GADOLINIUM-BASED CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%) AND MACROCYCLIC, LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018 V/S 2025) ($MN)
      • FIGURE 93     ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY MODALITY, AND CONTRAST AGENTS MARKET SHARE, BY IMAGING, (2018 V/S 2025) (%)
      • FIGURE 94     ASIA-PACIFIC CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 95     ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION AND END-USER, (2018 V/S 2025) (%)
      • FIGURE 96     ASIA-PACIFIC CONTRAST AGENTS MARKET SHARE, BY COUNTRY, (2018 V/S 2025) (%)
      • FIGURE 97     JAPAN CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
      • FIGURE 98     JAPAN CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 99     JAPAN CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
      • FIGURE 100     JAPAN CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
      • FIGURE 101     CHINA CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
      • FIGURE 102     CHINA CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 103     CHINA CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
      • FIGURE 104     CHINA CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
      • FIGURE 105     KOREA CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
      • FIGURE 106     KOREA CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 107     KOREA CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
      • FIGURE 108     KOREA CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
      • FIGURE 109     OTHER ASIA-PACIFIC COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
      • FIGURE 110     OTHER ASIA-PACIFIC COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 111     OTHER ASIA-PACIFIC COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
      • FIGURE 112     OTHER ASIA-PACIFIC COUNTRIES CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
      • FIGURE 113     REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY MOLECULE AND IODINE BASED CONTRAST AGENTS MARKET SHARE BY IONICITY, (2018 V/S 2025) (%)
      • FIGURE 114     REST OF THE WORLD IODINE BASED IONIC AND NON-IONIC CONTRAST AGENTS MARKET SHARE BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%)
      • FIGURE 115     REST OF THE WORLD GADOLINIUM-BASED CONTRAST AGENTS MARKET SHARE, BY CHEMICAL STRUCTURE, (2018 V/S 2025) (%) AND MACROCYCLIC, LINEAR CONTRAST AGENTS MARKET REVENUE, BY IONICITY, (2018 V/S 2025) ($MN)
      • FIGURE 116     REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY MODALITY, AND CONTRAST AGENTS MARKET SHARE, BY IMAGING, (2018 V/S 2025) (%)
      • FIGURE 117     REST OF THE WORLD CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 118     REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY ROUTE OF ADMINISTRATION AND END-USER, (2018 V/S 2025) (%)
      • FIGURE 119     REST OF THE WORLD CONTRAST AGENTS MARKET SHARE, BY COUNTRY, (2018 V/S 2025) (%)
      • FIGURE 120     BRAZIL CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
      • FIGURE 121     BRAZIL CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 122     BRAZIL CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
      • FIGURE 123     BRAZIL CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
      • FIGURE 124     REST OF LATAM CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
      • FIGURE 125     REST OF LATAM CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 126     REST OF LATAM CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
      • FIGURE 127     REST OF LATAM CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
      • FIGURE 128     MIDDLE EAST AND OTHERS CONTRAST AGENTS MARKET REVENUE, BY MOLECULE AND BY MODALITY, (2018 V/S 2025) ($MN)
      • FIGURE 129     MIDDLE EAST AND OTHERS CONTRAST AGENTS MARKET REVENUE, BY APPLICATION, (2018) ($MN)
      • FIGURE 130     MIDDLE EAST AND OTHERS CONTRAST AGENTS MARKET REVENUE, BY ROUTE OF ADMINISTRATION AND BY IMAGING, (2018 V/S 2025) ($MN)
      • FIGURE 131     MIDDLE EAST AND OTHERS CONTRAST AGENTS MARKET REVENUE, BY END-USER, (2018 V/S 2025) ($MN)
      • FIGURE 132     KEY GROWTH STRATEGIES (2016 – 2018)
      • FIGURE 133     SWOT: BAYER GROUP
      • FIGURE 134     SWOT: BEIJING BEILU PHARMACEUTICAL CO., LTD.
      • FIGURE 135     SWOT: BRACCO GROUP
      • FIGURE 136     SWOT: DONGKOOK LIFE SCIENCE
      • FIGURE 137     SWOT: FUJIFILM HOLDING CORPORATION
      • FIGURE 138     SWOT: FUJIPHARMA CO LTD
      • FIGURE 139     SWOT: GE HEALTHCARE
      • FIGURE 140     SWOT: GUERBET
      • FIGURE 141     SWOT: LANTHEUS MEDICAL IMAGING INC.
      • FIGURE 142     SWOT: SANOCHEMIA PHARMACEUTICAL AG
      • FIGURE 143     SWOT: TAEJOON PHARM CO., LTD.

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ALZECA BIOSCIENCES, INC.
      • 2     BAYER GROUP
      • 3     BEIJING BEILU PHARMACEUTICALS COMPANY LIMITED
      • 4     BIEM İLAÇ SAN. AND TIC, INC.
      • 5     BRACCO GROUP
      • 6     DAIHAN PHARM. CO. LTD.,
      • 7     DONGKOOK LIFESCIENCE
      • 8     FERRIC CONTRAST COMPANY
      • 9     FUJIFILM HOLDING CORPORATION
      • 10     FUJIPHARMA CO. LTD
      • 11     GE COMPANY (GE HEALTHCARE)
      • 12     GRATON PHARMA
      • 13     GUERBET, LLC
      • 14     HARMONY LIFE SCIENCES
      • 15     IMAX DIAGNOSTIC IMAGING LIMITED
      • 16     INLIGHTA BIOSCIENCES, LLC
      • 17     JB CHEMICALS AND PHARMACEUTICALS LTD
      • 18     JODAS EXPOIM PVT. LTD
      • 19     LANTHEUS MEDICAL IMAGING
      • 20     LIGAND PHARMACEUTICALS
      • 21     MAGNUS HEALTH
      • 22     NANO-THERAPEUTICS
      • 23     REGE IMAGING & CINEFILMS PRIVATE LIMITED
      • 24     SANOCHEMIA PHARMAZEUTIKA AG
      • 25     SPAGO IMAGING
      • 26     STELLENCE PHARMSCIENCE PRIVATE LIMITED
      • 27     TAEJOON PHARM CO. LTD.,
      • 28     TRIVITRON HEALTHCARE
      • 29     UNIJULES LIFE SCIENCES LTD
      • 30     UNIMARK REMEDIES
      • 31     ZHEJIANG STARRY PHARMA